🔍 Search
ParaneoplasticCommonICD-10 L29.x

Pruritus of malignancy

Paraneoplastic pruritus · malignancy-associated pruritus · cancer-related pruritus

Pruritus of malignancy is generalised itch occurring as a paraneoplastic or treatment-related phenomenon. Most strongly associated with haematological malignancy — particularly Hodgkin lymphoma (~30% have itch), polycythaemia vera (especially aquagenic), CTCL / mycosis fungoides and Sézary syndrome — but also reported with internal solid tumours (gastric, lung, hepatobiliary, pancreatic), cholestatic disease and as an immune-checkpoint-inhibitor adverse effect. UK BAD guidance and NICE NG12 recognise generalised pruritus >6 weeks as a malignancy red-flag.

CurrentLast reviewed 16 May 2026

Causes

  • Haematological malignancy:
    • Hodgkin lymphoma (~30%; classical generalised itch; sometimes "alcohol-induced" itch).
    • Non-Hodgkin lymphoma.
    • Cutaneous T-cell lymphoma / mycosis fungoides / Sézary.
    • Polycythaemia vera (~50%; aquagenic pruritus on contact with water).
    • Chronic lymphocytic leukaemia (CLL).
    • Multiple myeloma, myelodysplasia.
  • Solid organ malignancy:
    • Hepatobiliary / pancreatic — cholestatic itch (bile acids).
    • Gastric, lung, colorectal — paraneoplastic.
  • ICI / drug-induced:
    • Anti-PD-1 / PD-L1 / CTLA-4 — pruritus alone in ~10-20%; often early.
    • EGFRi-related (covered separately).
  • Treatment / disease-state:
    • Cholestasis from biliary obstruction.
    • Uraemia from renal failure (CKD pruritus, especially in chemotherapy / TLS).

Clinical features

  • Generalised itch — bath, evening predominance.
  • No primary cutaneous lesions; lesions are excoriation / lichen simplex / prurigo nodularis secondary.
  • Constitutional symptoms — fever, weight loss, night sweats, fatigue.
  • Lymphadenopathy / hepatosplenomegaly.
  • Aquagenic itch (polycythaemia vera): occurs after water contact, peaks at 10-30 minutes, lasts <1 hour.
  • Cholestatic itch: palms / soles predominant; jaundice; pale stools; dark urine.
  • Duration: chronic (>6 weeks generalised pruritus warrants malignancy workup).

Workup

  • History: B-symptoms, water-induced itch, drug history, recent ICI start, family history of haematological malignancy.
  • Examination: lymphadenopathy, hepatosplenomegaly, jaundice, skin lesions, neurology.
  • Bloods:
    • FBC + blood film (eosinophilia, atypical lymphocytes, polycythaemia).
    • U&E, LFT, calcium, ferritin, vitamin B12, folate, TSH.
    • Bilirubin, ALP, GGT (cholestasis).
    • LDH, ESR, CRP.
    • Serum / urine protein electrophoresis.
    • HIV, HBV / HCV.
  • Imaging: CT chest / abdomen / pelvis if lymphadenopathy, B-symptoms or unexplained.
  • Age- / sex-appropriate cancer screening; gastric / colon / lung review if indicated.
  • Skin biopsy if lesional, with TCR gene rearrangement to exclude MF; peripheral blood flow cytometry for Sézary cells.
  • Bone marrow if cytopenia or polycythaemia.

Differentials

  • Senile / xerotic pruritus — common in elderly; dry skin is the cause.
  • Atopic eczema, contact dermatitis.
  • Scabies, pediculosis.
  • Drug-induced pruritus.
  • Chronic urticaria.
  • Cholestatic itch from non-malignant liver disease (PBC, drug-induced).
  • Renal pruritus (uraemia).
  • Iron deficiency.
  • Thyroid disease (hypo- or hyperthyroidism).
  • Psychogenic itch.

Management

  • Treat underlying malignancy — itch resolves in most cases.
  • Symptomatic:
    • Bland emollients (urea-containing, menthol).
    • Mid-potency topical corticosteroid for excoriated areas.
    • Capsaicin 0.025-0.075% locally.
    • Sedating antihistamines (hydroxyzine, doxepin); H1 + H2 combination.
    • Cool compresses, lukewarm baths.
  • Systemic:
    • Gabapentin 300-2400 mg / day (especially renal / CTCL / uraemic itch).
    • Pregabalin.
    • Mirtazapine 15-30 mg nocte.
    • Doxepin 10-25 mg nocte.
    • Naltrexone (off-label) for cholestatic and aquagenic itch.
  • Polycythaemia vera aquagenic pruritus:
    • Hydroxycarbamide, interferon, ruxolitinib.
    • Aspirin.
  • Cholestatic itch:
    • Cholestyramine (bile-acid sequestrant).
    • Rifampicin 150-600 mg.
    • Naltrexone.
    • Plasmapheresis for refractory itch.
  • ICI-induced pruritus:
    • Mild (G1-G2): topical steroids, antihistamines; do not interrupt ICI.
    • Moderate-severe: oral steroids; consider dupilumab (case series); consider holding ICI if persistent G3.
  • Phototherapy: NBUVB for refractory pruritus (especially uraemic, CTCL).

References

  1. Yosipovitch G et al. Itch. N Engl J Med. 2013;368:1625-1634.
  2. Krajnik M, Zylicz Z. Understanding pruritus in systemic disease. J Pain Symptom Manage. 2001;21:151-168.
  3. Weisshaar E et al. European guideline on chronic pruritus. Acta Derm Venereol. 2012;92:563-581.
  4. NICE NG12. Suspected cancer: recognition and referral. London: NICE; 2015 (last updated 15 April 2026).
  5. Sibaud V et al. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol. 2016;28:254-263.

Spot a correction?

If any clinical statement, citation or link on this page needs updating, please email admin@skinoncology.net with the page name, the proposed correction and the supporting source.